AGH heart specialists to join clinical trial
Heart specialists at Allegheny General Hospital announced today that they will join a clinical trial investigating an implantable device designed to provide patients with coronary artery disease an early warning of an impending heart attack.
AGH is the only Pittsburgh area hospital testing the new device — the AngelMed Guardian System.
"Patient outcomes following heart attack are largely dependent upon how quickly the cardiac injury is diagnosed and therapeutic efforts are initiated to restore blood flow to the heart. Delays in that process can result in permanent damage to heart muscle," said Dr. David Lasorda, director of the hospital's division of Interventional cardiology and its principal investigator in the study.
The American Heart Association estimates that one of every five deaths in the United States is attributable to coronary heart disease. Furthermore, 50 percent of heart-attack fatalities occur within one hour of symptom onset and often before the patient even reaches the hospital.
TribLive commenting policy
You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.
We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.
While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.
We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments â either by the same reader or different readers.
We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.
We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.
We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.
We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.